Coronavirus 3C-like protease (3CLpro) (3CLpro)

The Coronavirus 3C-like protease (3CLpro), also known as the main protease (Mpro), is a key enzyme essential for the replication of coronaviruses, including SARS-CoV-2, SARS-CoV, and MERS-CoV (UniProt: P0C6U8). It functions as a homodimeric cysteine protease that cleaves the viral polyproteins pp1a and pp1ab at eleven specific sites, releasing functional non-structural proteins (nsps) that form the viral replication-transcription complex (PubMed: 32272481). Because 3CLpro has a unique substrate specificity—cleaving after a glutamine residue—which is not shared by any known human host cell proteases, it serves as an ideal target for highly selective antiviral therapy (NIH: PMC7153422). Therapeutic agents such as nirmatrelvir and ensitrelvir act by binding to the active site of the enzyme, effectively blocking its catalytic activity and halting the viral life cycle (PubChem: CID 155903259). In clinical settings, these inhibitors are used to treat COVID-19, significantly reducing the risk of progression to severe disease in vulnerable populations. However, the potential for drug-drug interactions, particularly when 3CLpro inhibitors are combined with pharmacokinetic enhancers like ritonavir, remains a significant clinical consideration (FDA: Paxlovid Fact Sheet). Additionally, the emergence of mutations in the nsp5 gene requires continuous surveillance to monitor for the development of antiviral resistance.

Other names

Main proteaseMproNon-structural protein 5nsp53CL proteaseSARS-CoV-2 3C-like protease

Inhibition of the 3C-like protease prevents the cleavage of viral polyproteins pp1a and pp1ab into functional non-structural proteins, which are essential for the assembly of the viral replication-transcription complex, thereby halting viral replication (PubMed: 32272481).